Isocarboxazid: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(3 intermediate revisions by one other user not shown)
Line 9: Line 9:
|blackBoxWarningTitle=Warning Title
|blackBoxWarningTitle=Warning Title
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|fdaLIADAdult=*Depression
:*Initial: 20 mg/day PO into 2 doses, increase every 2-4 days by 10 mg, to a maximum of 40 mg in first week. Then increase to 20 mg/week to a max of 60 mg/day.
:*Maintenance: Decrease dose slowly to minimum effective dosage
|offLabelAdultGuideSupport=There is limited information about <i>Off-Label Guideline-Supported Use</i> of Isocarboxazid in adult patients.
|offLabelAdultNoGuideSupport=There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Isocarboxazid in adult patients.
|fdaLIADPed=safety in under 16 years of age have not been established.
|offLabelPedGuideSupport=There is limited information about <i>Off-Label Guideline-Supported Use</i> of Isocarboxazid in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information about <i>Off-Label Non–Guideline-Supported Use</i> of Isocarboxazid in pediatric patients.
|drugBox={{Drugbox 2
|drugBox={{Drugbox 2
| Verifiedfields = changed
| Verifiedfields = changed
Line 66: Line 74:
}}
}}
{{PillImage
{{PillImage
|fileName=Marplan
|fileName=No_image.jpg
|drugName=Isocarboxazid
|drugName=Isocarboxazid
|NDC=30698-032-01
|NDC=30698-032-01
|drugAuthor=Validus Pharmaceuticals LLC
|drugAuthor=Validus Pharmaceuticals LLC
|ingredients= lactose, starch, corn, povidone, d&c red no. 27, fd&c yellow no. 6, magnesium stearate
|ingredients=lactose, starch, corn, povidone, d&c red no. 27, fd&c yellow no. 6, magnesium stearate
|pillImprint=MARPLAN;10
|pillImprint=MARPLAN;10
|dosageValue=10.00
|dosageValue=10.00
Line 79: Line 87:
|pillScore=2
|pillScore=2
}}
}}
{{LabelImage}}
{{LabelImage
|fileName=Isocar1.jpeg
}}
{{LabelImage
|fileName=Isocar2.PNG
}}

Latest revision as of 14:35, 2 August 2015

Isocarboxazid
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)

Overview

Isocarboxazid is a MAOI that is FDA approved for the {{{indicationType}}} of depression. There is a Black Box Warning for this drug as shown here. Common adverse reactions include constipation, nausea, xerostomia, dizziness, headache, insomnia..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Depression
  • Initial: 20 mg/day PO into 2 doses, increase every 2-4 days by 10 mg, to a maximum of 40 mg in first week. Then increase to 20 mg/week to a max of 60 mg/day.
  • Maintenance: Decrease dose slowly to minimum effective dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information about Off-Label Guideline-Supported Use of Isocarboxazid in adult patients.

Non–Guideline-Supported Use

There is limited information about Off-Label Non–Guideline-Supported Use of Isocarboxazid in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

safety in under 16 years of age have not been established.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information about Off-Label Guideline-Supported Use of Isocarboxazid in pediatric patients.

Non–Guideline-Supported Use

There is limited information about Off-Label Non–Guideline-Supported Use of Isocarboxazid in pediatric patients.

Contraindications

There is limited information regarding Isocarboxazid Contraindications in the drug label.

Warnings

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)

There is limited information regarding Isocarboxazid Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Isocarboxazid Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Isocarboxazid Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Isocarboxazid Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Isocarboxazid in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Isocarboxazid in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Isocarboxazid during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Isocarboxazid in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Isocarboxazid in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Isocarboxazid in geriatric settings.

Gender

There is no FDA guidance on the use of Isocarboxazid with respect to specific gender populations.

Race

There is no FDA guidance on the use of Isocarboxazid with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Isocarboxazid in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Isocarboxazid in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Isocarboxazid in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Isocarboxazid in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Isocarboxazid Administration in the drug label.

Monitoring

There is limited information regarding Isocarboxazid Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Isocarboxazid and IV administrations.

Overdosage

There is limited information regarding Isocarboxazid overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Template:Drugbox 2

Mechanism of Action

There is limited information regarding Isocarboxazid Mechanism of Action in the drug label.

Structure

There is limited information regarding Isocarboxazid Structure in the drug label.

Pharmacodynamics

There is limited information regarding Isocarboxazid Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Isocarboxazid Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Isocarboxazid Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Isocarboxazid Clinical Studies in the drug label.

How Supplied

There is limited information regarding Isocarboxazid How Supplied in the drug label.

Storage

There is limited information regarding Isocarboxazid Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Isocarboxazid |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Isocarboxazid |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

(Patient Counseling Information)

Precautions with Alcohol

Alcohol-Isocarboxazid interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Isocarboxazid Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Isocarboxazid Look-Alike Drug Names in the drug label.

Drug Shortage Status

Drug Shortage

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject: 

 |Page Name=Isocarboxazid
 |Pill Name=No_image.jpg
 |Drug Name=Isocarboxazid
 |Pill Ingred=lactose, starch, corn, povidone, d&c red no. 27, fd&c yellow no. 6, magnesium stearate|+sep=;
 |Pill Imprint=MARPLAN;10
 |Pill Dosage=10.00 mg
 |Pill Color=Orange|+sep=;
 |Pill Shape=Round
 |Pill Size (mm)=9.00
 |Pill Scoring=2
 |Pill Image=
 |Drug Author=Validus Pharmaceuticals LLC
 |NDC=30698-032-01

}}

{{#subobject: 

 |Label Page=Isocarboxazid
 |Label Name=Isocar1.jpeg

}}

{{#subobject: 

 |Label Page=Isocarboxazid
 |Label Name=Isocar2.PNG

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Isocarboxazid&oldid=1126345"